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Abstract
INTRODUCTION: The basaloid triple-negative breast cancer (B-TNBC) is one of themost aggressive, therapy-resistant,
and metastatic tumors. Current models do not recapitulate the basaloid phenotype of TNBC, thus limiting the under-
standing of its biology and designing new treatments. We identified HCC1806 as a line expressing typical B-TNBC
markers, engineered a subline with traceable reporters, and determined growth, drug sensitivity, recurrence, and
vascular and metastatic patterns of orthotopic xenografts in immunodeficient mice. METHODS: mRNA and protein
analyses showed that HCC1806 expresses basal but not luminal or mesenchymal markers. HCC1806-RR subline
stably expressing red fluorescent protein and Renilla luciferase was generated and characterized for sensitivity to
chemodrugs, orthotopic growth, vascular properties, recurrence, metastasis, and responsiveness in vivo. RESULTS:
The HCC1806 cells were highly sensitive to paclitaxel, but cytotoxicity was accompanied by pro-survival vascular
endothelial growth factor–A loop. In vivo, HCC1806-RR tumors display linear growth, induce peritumoral lymphatics,
and spontaneously metastasize to lymph nodes (LNs) and lungs. Similarly to human B-TNBC, HCC1806-RR tumors
were initially sensitive to taxane therapy but subsequently recur. Bevacizumab significantly suppressed recurrence by
50% and reduced the incidence of LN and pulmonary metastases by, respectively, 50% and 87%. CONCLUSIONS:
The HCC1806-RR is a new model that expresses bona fide markers of B-TNBC and traceable markers for quantifying
metastases. Combination of bevacizumab with nab-paclitaxel significantly improved the outcome, suggesting that this
approach can apply to human patients with B-TNBC. This model can be used for defining themetastatic mechanisms of
B-TNBC and testing new therapies.
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Introduction
Breast cancer is the second leading cause of cancer-related deaths in
the United States with 40,000 deaths and 200,000 new cases diag-
nosed annually [1]. Approximately 15% to 19% of patients are diag-
nosed with triple-negative breast cancer (TNBC) [2–5], which are
mammary tumors that lack receptors for estrogen (ER), progesterone
(PR), and human epidermal growth factor receptor 2 (HER2) [4,6].
TNBC is most common in women who are obese, premenopausal, of
low socioeconomic status, or of African American descent [7–9]. This
is a particularly lethal subtype of breast cancer with a 5-year survival
rate as low as 40% [10–12]. Patients with TNBC have a high fre-
quency of lymphatic [6,12,13] and distant metastasis [11,14] and,
consequently, a significantly greater risk for recurrence and shortened
survival compared with patients with ER/PR-positive tumors [10,13].
The life expectancy after detection of visceral metastasis in TNBC
patients is estimated as 3 to 22 months [12,15].
Although, biologically and genetically, TNBC is a heterogeneous
group of tumors [16], the majority (∼80–90%) falls into the classifica-
tion of basal-like subtype [5,17]. Basaloid TNBC (B-TNBC) is char-
acterized by expression of cytokeratins 5, 6, 14, and 17 [3,6,18,19],
epidermal growth factor receptor (EGFR) [3,20,21], c-Kit [3], mutated
BRCA1 [3,14,21], and mutated or deleted p53 [22,23]. Patients with
B-TNBC have higher tumor mitotic index [24] and a worse prognosis
than patients with triple-negative tumors that do not express basal
markers [3,17,25]. B-TNBC subgroup has a tendency to generate
larger tumors [19] with frequent lymphovascular invasion [26,27]
and metastasis to multiple sites, whereas nonbasaloid tumors typically
metastasize only to one site [17]. Despite generally poor prognosis for
B-TNBC patients, these tumors are sensitive to cytotoxic therapy
[6,13,14,28] with one study demonstrating the highest response rate
(85%) of all breast cancer subtypes [14]. However, despite the initial
response, patients with TNBC tumors had the worst disease-free and
overall survival of all subtypes [14,29], presumably because of the
tendency of these tumors to recur at distant sites [14].
Despite the well-known challenges to successful treatment of
B-TNBC, little is known about the unique properties of this cancer
that predispose patients to metastasis and tumor recurrence. This is
mainly because of paucity of reliable in vivo models that faithfully
recapitulate major attributes of this disease, particularly those of the
basaloid group. On the basis of hierarchical clustering analyses of
microarray studies, several breast carcinoma cell lines are qualified to
represent the ER/PR/HER2-negative TNBC group. The most fre-
quently suggested lines in this list are HCC38 [30–32], HCC70
[30–32], HCC1937 [30–32], MDA-MB-468 [32], MDA-MB-231
[32–34], and HCC1806 [30–32,35]. However, the potential of these
lines to serve as an animal TNBC model is still uncertain because, with
the exception of MDA-MB-231 [36,37], most of these lines have
not been tested for the ability to grow in vivo. Some lines (e.g.,
MDA-MB-468 and HCC1806) are known to generate tumors in
mice; however, these tumor models have not been quantitatively
assessed for recurrence and metastasis, the two main B-TNBC prop-
erties that cause patient death.
Of the aforementioned lines, MDA-MB-231 deserves special dis-
cussion because it is the most frequently used TNBC model and is
considered to represent the basaloid subtype of TNBC [32–34,38–40].
In contrast to other lines, both unmodified and luciferase-tagged
MDA-MB-231 sublines have been extensively characterized for growth
patterns at the orthotopic site in vivo including quantitative assess-
ment of kinetics, burden, and organ distribution of spontaneous
metastasis to lymph node (LN) and lungs [36,37]. Although this
metastatic behavior and lack of ER/PR/HER2 markers are both
consistent with B-TNBC phenotype, neither the MDA-MB-231
cell line nor all other candidates for TNBC models have been
previously tested for the expression of basal cytokeratins 5, 6, 14,
and 17. Moreover, MDA-MB-231 cells express a broad variety of
mesenchymal-specific proteins including vimentin [20], which places
this line into the mesenchymal [20] or mesenchymal stem–like
[31] TNBC category that has distinct molecular signature and drug
sensitivity from those in the basaloid group [31]. The source of the
MDA-MB-231 line is thought to be a rare type of breast cancer pos-
itive for myoepithelial markers [20,41] that is heterogeneously de-
scribed as metaplastic [41], sarcomatoid, or spindle cell carcinomas
[20,42]. The incidence of this tumor type is reportedly 0.02% [43]
to 0.2% [44], which is a likely reason for the absence of mesenchy-
mal samples among the typical collection of breast cancer specimens
[20]. The rarity of this subtype among clinical samples and the dis-
tinct genetic profile of this line create a problem with classification
of MDA-MB-231 as a B-TNBC prototype. Ultimately, information
derived from studies using this model may not be applicable to clin-
ical B-TNBC.
With these limitations in mind, we sought to establish a bona fide
B-TNBC model that would comply with the following require-
ments: 1) lack of ER/PR/HER2 as a general marker of all TNBC
subtypes; 2) lack of vimentin that is expressed in myoepithelial but
not basal epithelial cells [45]; 3) expression of basal cytokeratins 5, 6,
14, and 17 as clear evidence for basal origin [46]; 4) ability to grow at
the orthotopic site in mice [i.e., mammary fat pad (MFP)]; 5) ability
to spontaneously metastasize from the orthotopic site to LNs and
visceral organs mimicking the high metastatic potential of B-TNBC
[6,11]; 6) and lastly, ability to initially respond to cytotoxic therapy
followed by rapid recurrence, as a well-documented feature of clinical
B-TNBC [47].
After extensive search and several pilot studies with different
lines, we determined that the HCC1806 cell line complies with
all of the above requirements. This line was established from a tu-
mor of a patient with TNBC [30] and was subsequently confirmed
to lack ER/PR/HER2 [30] as well as p53 [48], another marker of
aggressive breast cancers. The consistency of the HCC1806 genetic
profile with the basaloid subgroup of TNBC type has been re-
cently confirmed by a microarray study classifying a heterogeneous
TNBC group into seven subtypes with defined molecular signa-
tures and sensitivity to drugs [31]. Here, after verifying the basaloid
nature of HCC1806 cell line in our laboratory, we genetically mod-
ified this line for expression of bioluminescent and fluorescent re-
porter genes, validated in vitro and in vivo its growth patterns, and
quantitatively determined the metastatic incidence, burden, and
spread to normal organs in mice. We also characterized the sensi-
tivity of HCC1806 cells to commonly used anticancer drugs and
analyzed the unique properties of blood and lymphatic vessels in
HCC1806 tumors in vivo that might contribute to biologic behav-
ior of B-TNBC. Lastly, we assessed the responsiveness of this new
B-TNBC model to a combination of nab-paclitaxel and bevacizumab,
a therapy that was highly successful in other models of aggres-
sive breast cancer [36,37]. Collectively, these studies provide a de-
tailed in vitro and in vivo characterization of a novel B-TNBC model
that should be useful for defining unique biologic mechanisms
causing patient mortality and for assessing effective therapies to
counteract them.
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Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM) and standard
additives were obtained from Lonza (Basel, Switzerland). Ketamine
and xylazine were purchased from Phoenix Scientific (St Joseph,
MO). Endotoxin-free sterile 0.9% NaCl solution (saline) and protease
inhibitors were from Sigma-Aldrich (St Louis, MO). Matrigel was from
BD Biosciences (Franklin Lakes, NJ).
Study Drugs
Paclitaxel formulated as albumin-bound particles for injectable
suspension (nab-paclitaxel, Abraxane) was obtained from Celgene,
formerly Abraxis BioScience (Los Angeles, CA). Paclitaxel (Taxol)
was obtained from Bristol-Myers Squibb (New York, NY). Perifosine
was obtained from Cayman Chemical Company (Ann Arbor, MI).
Doxorubicin was obtained from Teva Parenteral Medicines, Inc.
(Irvine, CA). Cis-diammineplatinum(II) dichloride (cisplatin) was
purchased from Sigma. Erlotinib (Tarceva) was obtained from OSI
Pharmaceuticals (Melville, NY). Bevacizumab (Avastin), humanized
anti–vascular endothelial growth factor–A (VEGF-A) antibody, manu-
factured by Genentech (San Francisco, CA), was obtained from a local
pharmacy. Drugs were reconstituted in saline, prepared fresh daily, and
used within 1 hour of preparation.
Antibodies
We used the following primary antibodies: rabbit anti-cytokeratin 5,
6, and 14 (Abcam, Cambridge, MA); rat anti-mouse MECA-32 and
mouse anti–β-actin (Developmental Studies Hybridoma Bank, Iowa
City, IA); rat anti-mouse LYVE-1 (R&D Systems, Minneapolis,
MN); and rabbit anti–Renilla luciferase (Rluc; MBL, Woburn, MA).
Secondary IR680-conjugated donkey anti-mouse and anti-rabbit anti-
bodies (LI-COR, Lincoln, NE) and secondary DyLight 488– and
DyLight 549–conjugated donkey anti-rabbit and anti-rat antibodies
were from Jackson ImmunoResearch Laboratories (West Grove, PA).
Culture of Human HCC1806 Breast Carcinoma Cell Line and
Its Derivatives
HCC1806 cell line was purchased from ATCC (Rockville, MD)
and cultured in DMEM containing 5% FBS, 2 mM glutamine, 1 mM
sodium pyruvate, and 1 mM nonessential amino acids at 37°C in 10%
CO2. Cells were passaged biweekly by incubating for 5 minutes at 37°C
first in 0.5 mM EDTA dissolved in Dulbecco phosphate-buffered
saline (PBS) followed by 0.5% of trypsin. Cells were routinely tested
for mycoplasma using immunodetection kit from Roche Diagnostics
GmbH (Penzberg, Germany).
Total RNA Extraction and Reverse Transcription–Polymerase
Chain Reaction and Reverse Transcription–Quantitative
Polymerase Chain Reaction Analyses
Total RNA extracted by using TRI-reagent (Sigma-Aldrich) was re-
verse transcribed with RevertAid H Minus First Strand cDNA Synthe-
sis Kit (Fermentas, Glen Burnie, MD) according to the manufacturer’s
instructions. Endpoint reverse transcription–polymerase chain reaction
(RT-PCR) analysis was performed as previously described [49] using
Apex TaqDNA Polymerase (Genesee Scientific, San Diego, CA). Gels
were visualized and analyzed using a FluroChem 5500 imager
(AlphaInnotech, San Leandro, CA). RT–quantitative PCR (RT-qPCR)
was performed using Go Taq Green Master Mix (Promega, Madison,
WI). Products were analyzed using ABI 7500 Real-Time System
(Applied BioSystems, Foster City, CA). Data were normalized to
β-actin and relative mRNA expression was determined using the ΔΔC t
method. All primers used in this study are listed in Table W1.
Western Blot Analysis
MCF-7, MDA-MB-231, andHCC1806 cell pellets were lysed in ice-
cold buffer [50 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium
dodecyl sulfate, phenylmethylsulfonyl fluoride (1:100), and protease
inhibitor cocktail (1:50)]. Proteins separated in 12% sodium dodecyl
sulfate–polyacrylamide gel were transferred onto nitrocellulose mem-
branes followed by overnight incubation with primary antibodies
against cytokeratins 5, 6, and 14 and β-actin. After a 1-hour incubation
with IR680-conjugated secondary antibodies, blots were washed and
imaged using Odyssey Infrared Imager 2.0 (LI-COR).
Generation and Characterization of HCC1806 Cells Tagged
with Red Fluorescent Protein and Rluc
HCC1806 cells were seeded in a six-well plate at the density of
100,000 cells per well. Cells were allowed to attach overnight, washed,
and fed with fresh medium before transfection. Cells were transfected
with a mixture of plasmids in which pKT2/red fluorescent protein
(RFP)–Renilla–neomycin, pKT2/CAAGS-ires-puro, and Sleeping
Beauty (SB) transposase–encoding vectors were present at the ratio of
1:1:4, respectively. Plasmids were mixed with lipofectamine and the
transfection mixture was incubated with cells overnight. The follow-
ing day, cells were washed with Dulbecco PBS, fed with fresh growth
medium, and allowed to recover for 48 hours before selection with
puromycin (1 μg/ml) for 7 to 10 days. Puromycin-resistant cells were
assessed for RFP expression by direct fluorescent microscopy and sub-
cloned to obtain monoclonal isolates. HCC1806 clones demonstrating
identical morphology and growth potential (calculated by doubling
time) to the parental line were selected and designated as HCC1806-
RR to indicate the expression with both RFP and Rluc. The selected
clones were expanded and extensively tested for growth and metastatic
distribution in vivo. Only those clones that had identical growth and
metastatic patterns to the parental line were selected for further studies.
Determination of Rluc Activity in HCC1806-RR Subclones
Viable cells identified by trypan blue exclusion were serially di-
luted in 1.5-ml tubes to generate a standard curve ranging from 780
to 100,000 cells per tube. Cells were pelleted by centrifugation at
13,000 rpm for 10 minutes, resuspended in 150 μl of the passive
lysis buffer (Promega), and placed on ice for 10 minutes before being
cleared of insoluble material by additional centrifugation at 13,000 rpm
for 10 minutes. Ten microliters of whole-cell lysate was added to 50 μl
of Rluc substrate (Biosynth, Rietlistr, Switzerland), and luciferase
activity was measured for 10 seconds using a single-tube luminometer
(Berthold Technologies, Oakridge, TN). All measurements were done
in triplicate and the results are presented as mean of relative light units
per second (RLU/s) ± SD. Luciferase expression per cell was calculated
by dividing the mean RLU/s by cell number in each tube.
Proliferation Assay of Parental and HCC1806-RR Lines
In Vitro
HCC1806 parental or HCC1806-RR cells (15,000/well) were
seeded in triplicate into 24-well plates supplemented with 500 μl
of growth medium in triplicate wells for each time point. Cells were
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trypsinized and counted every 24 hours for 96 hours. The results are
presented as the mean values ± SD of the two independent experi-
ments performed. The difference in proliferation between the parental
and HCC1806-RR cell lines was assessed by a Student’s t test consid-
ering P values less than .05 as significant.
Determination of In Vitro Sensitivity of MDA-MB-231 and
HCC1806 Cell Lines to Commonly Used Anticancer Drugs
MDA-MB-231 and HCC1806-RR cells were seeded into a 24-well
plate at a density of 50,000 cells per well in a volume of 500 μl of
growth medium. After overnight incubation to allow for attachment
without drugs, cells were treated with a range of doses of nab-paclitaxel,
paclitaxel, perifosine, doxorubicin, cisplatin, erlotinib, or bevacizumab.
Viable cell counts were determined after 48 hours of exposure to the
drugs using trypan blue exclusion method. Each point was performed
in duplicate and all experiments were repeated twice. The dose-
response curve was constructed on the basis of the number of cells that
survived after a 48-hour exposure to each drug concentration. The half-
maximal inhibitory concentration (IC50) of each drug that was cal-
culated on the basis of this curve represents a drug concentration that
kills 50% of the cells as compared with untreated or vehicle-treated
control cells.
Characterization of Tumor Growth of HCC1806 and
HCC1806-RR Lines In Vivo
Four million HCC1806 parental or HCC1806-RR cells suspended
in a solution of 50% Matrigel in DMEM (100 μl) were orthotopically
implanted in the MFP of 4- to 6-week-old female nu/numice (Harlan,
Indianapolis, IN), as previously described [36,37,49]. Every 2 to
3 days, perpendicular tumor diameters were measured by digital caliper
and used to calculate tumor volume according to the formula: volume =
Dd 2π/6, where D equals the larger diameter and d equals the smaller
diameter. The care, drug treatment, and all procedures including sacri-
fice of the animals were performed in accordance with the protocols
approved by the Laboratory Animal Care and Use Committee of
Southern Illinois University School of Medicine.
Assessment of Bioluminescence of Primary Tumors and
Metastatic Lesions
Mice were injected intravenously (i.v.) with 2 mg/kg Rluc substrate,
colenterazine (Biotium, Hayward, CA). The substrate was allowed to
circulate for approximately 5 minutes before anesthetizing mice with
a ketamine/xylazine cocktail. Bioluminescence was detected using
Xenogen Ivis Lumina (Caliper Life Sciences, Hopkinton, MA) for
3 to 10 minutes. After imaging, mice were killed, and all major organs
were collected for quantitative assessment of metastatic burden.
Determination of Metastatic Burden
Tissues were homogenized in ice-cold passive lysis buffer (Promega)
containing protease inhibitors. Rluc substrate (50 μl) was mixed with
lysates (10 μl) followed by luminescence detection using a luminometer
(Berthold Technologies). Luminescence detected for the buffer alone
was subtracted from the results. Data are expressed as the mean
RLU/s ± SD from duplicate readings normalized per milligram of total
protein determined by Bradford assay. Extracts with luciferase activity
of 1500 RLU/s above background were considered positive for metas-
tasis. This value was based on established correlation between the lucif-
erase activity of the lysates and the ability to identify metastatic lesions
by tissue staining with tumor-specific markers.
Immunohistochemical Analysis of Blood Vessels, Lymphatic
Vessels, and Rluc-tagged Tumor Cells
Staining was performed on 8-μm-thick sections that were produced
from snap-frozen HCC1806-RR tumors. Slides were equilibrated to
room temperature for 20 minutes, fixed in acetone for 10 minutes,
and rehydrated in PBS with 0.1% Tween 20. Antibodies against Rluc
and mouse LYVE-1 were diluted 1:100, and MECA-32 hybridoma
conditioned medium was used undiluted. All primary and secondary
antibodies were incubated on the slides for 1 hour at 37°C and washed
for 10 minutes in PBS with 0.1% Tween 20 after each incubation.
After the last wash, slides were mounted in VectaShield medium con-
taining 4,6′-diamidino-2-phenylindole nuclear stain (Vector Labs,
Orton, Southgate, United Kingdom). Images were acquired on an
Olympus upright BX41 microscope equipped with a DP70 digital
camera and DP Controller software (Olympus, Center Valley, PA).
Measurement of Mean Vascular Area
The mean vascular area of MECA-32–positive staining per field
was calculated as described [50], with slight modifications. Briefly,
200× magnified fluorescent images were acquired from MECA-32–
stained tumor and normal MFP sections at a constant exposure using
an Olympus BX41 microscope, as described above. Each experimen-
tal group was represented by four tumors or MFPs derived from in-
dividual mice (n = 4) from which four randomly selected images were
acquired. The area of five to eight blood vessels in each image were
measured using Image J software (http://rsbweb.nih.gov/ij/), and the
values for each group were averaged. Twenty to thirty-two blood vessels
were analyzed per group. The results are presented as the mean vascular
area ± SEM.
Kinetics of VEGF-A Protein Secretion In Vitro Determined
by ELISA
HCC1806-RR cells were seeded in a six-well plate at a density of
500,000 cells in 2 ml of growth medium. The cells were allowed to
attach overnight before treatment with 10 nM nab-paclitaxel for 0, 2,
6, 24, 48, and 72 hours. Collected conditioned medium was concen-
trated 2.7-fold by low-speed centrifugation through Amicon concen-
trators with 10-kDa cutoff membrane (Millipore, Bellerica, MA).
VEGF-A ELISA Kit was purchased from Peprotech (Rocky Hill, NJ)
and performed as directed except that visualization of VEGF-A binding
to antibody was detected by using the TMB development solution
(Scytek, Logan, UT). All measurements were reproduced twice. Results
are presented as the mean pg ± SD of VEGF-A normalized per 106 cells
of four independently obtained values derived from two experiments
performed in duplicate.
Assessment of Pro-survival Effect of VEGF-A on
Paclitaxel-treated HCC1806-RR Cells
HCC1806-RR cells were seed in a 24-well plate at a density of
50,000 cells in 0.5 ml of growth medium. The cells were allowed
to attach for 2 hours and then treated with VEGF-A isoform 121
(VEGF-A121 or V121; 10–200 ng/ml), VEGF-A isoform 165
(VEGF-A165 or V165; 10–200 ng/ml), or bevacizumab (5 μg/ml) over-
night. Cells were then treated with nab-paclitaxel (0.19–25 nM) for
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72 hours. Cells were then trypsinized and enumerated. Each point was
performed in duplicate and all experiments were repeated twice. Data
were presented as the mean percent of untreated control ± SD.
Tumor Treatment with Nab-Paclitaxel and Bevacizumab
In Vivo
Mice bearing established HCC1806-RR tumors with a mean vol-
ume of 150 mm3 were randomized into four groups (six to eight mice
per group) and treated with saline (control), nab-paclitaxel alone
(10 mg/kg, i.v., daily for five consecutive days), bevacizumab alone
[4 mg/kg, intraperitoneally (i.p.), biweekly], or nab-paclitaxel com-
bined with bevacizumab. Nab-paclitaxel course was given for one
cycle. Bevacizumab treatment began 24 hours after the first nab-
paclitaxel injection and continued for the study’s duration. The con-
trol group received saline (0.1 ml), injected i.v. or i.p. on the same
days as nab-paclitaxel and bevacizumab treatments, respectively. Mice
were sacrificed when tumor volumes in the control group reached
1800 mm3. Metastasis was quantified by determining protein-
normalized luciferase activity in tissue extracts of ipsilateral LNs (ILNs),
contralateral LN (CLN), and lungs.
Statistical Analysis
Statistical analysis was performed using SPSS 14.0 (SPSS, Chicago,
IL). Results are expressed as mean ± SE. Statistically significant differ-
ences in tumor volume among experimental groups were determined
by Student’s t test. Statistically significant differences in incidence and
burden of metastases were determined by Fisher exact and Wilcoxin
ranked sums tests, respectively. The P values less than .05 were
considered as significant for each test.
Results
HCC1806 Cell Line Expresses Typical Markers of B-TNBC
Few cell models that effectively recapitulate clinical B-TNBC are
available, limiting our understanding of TNBC biology and ability to
assess potential therapies. Despite findings that several cell lines dis-
play the clinical hallmarks of TNBC [31] (i.e., the absence of ER,
PR, and HER2), none of the available lines have been characterized
in details for consistency with other markers of B-TNBC as well as
the ability to mimic typical clinical manifestations of this subgroup.
We sought to establish a new model that both faithfully represented
the unique molecular features of B-TNBC and mimics its biologic
behavior in vivo.
During the search for this model, we identified HCC1806 as a cell
line that had been established from a patient with TNBC and sub-
sequently confirmed to lack hormonal receptors and HER2 [30]. To
determine whether the HCC1806 line displayed distinct markers of
the B-TNBC subgroup, we analyzed HCC1806 cells by RT-PCR
and RT-qPCR for the expression of hormonal receptors, HER2,
and luminal, basal, and mesenchymal markers (Figure 1, A–E ). Ad-
ditionally, protein expression of basal cytokeratins 5, 6, and 14 was
assessed by Western blot (Figure 1F ). The profile of HCC1806 was
compared with profiles of MCF-7 line representing luminal A sub-
type [2] and MDA-MB-231 line currently considered as a represen-
tative of human B-TNBC [32,33,38].
Consistent with prior report [31], MCF-7 expressed hormonal
receptors and HER2, whereas both MDA-MB-231 and HCC1806
lines lacked these receptors (Figure 1A). Luminal cytokeratins 8, 18,
and 19 were expressed in all three lines with MCF-7 demonstrating
the highest expression compared with MDA-MB-231 and HCC1806
(Figure 1B). EGFR, a signaling receptor with propensity to be over-
expressed in B-TNBC [3], was detected in both MDA-MB-231 and
HCC1806 lines (Figure 1C ), indicating some commonality in gene
expression between two lines. In sharp contrast, well-documented
markers of B-TNBC such as basal cytokeratins 5, 6, 14, and 17
[17–19,51] were present exclusively in HCC1806 cells but not in
MCF-7 or MDA-MB-231 cells (Figure 1, C and E). This has been
confirmed in both using RT-PCR and RT-qPCR assays and indepen-
dent pairs of primers (Table W1), suggesting that HCC1806 (but not
MDA-MB-231) cell line is derived from the basaloid origin. This was
further confirmed by analysis of the expression of a bona fide mes-
enchymal marker vimentin that was present at high levels in MDA-
MB-231 cells but not in HCC1806 or MCF-7 (Figure 1D). This
was further confirmed by Western blot analysis demonstrating protein
expression of basal cytokeratins 5, 6, and 14 in HCC1806 but not
in MDA-MB-231 cells (Figure 1F ). These data show that although
MDA-MB-231 and HCC1806 lines share some features of TNBC,
only the latter expresses all typical markers of the B-TNBC. Con-
versely, MDA-MB-231 is more accurately classified as a mesenchymal
or mesenchymal stem–like TNBC line [31] rather than basal-like, as
suggested by some previous studies [33,38].
Figure 1. Selection of a cell line that represents B-TNBC. MCF-7,
MDA-MB-231, and HCC1806 were screened by endpoint RT-PCR
for expression of (A) hormone receptors and HER2, (B) luminal
cytokeratins, (C) basal cytokeratins, and (D) vimentin, a mesen-
chymal marker. (E) Basal markers and vimentin were confirmed
by RT-qPCR and normalized to β-actin presented as dC t ± SE.
(F) Protein expression of basal cytokeratins 5, 6, and 14 was also
confirmed by Western blot analysis in which β-actin demonstrated
equal protein loading.
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Generation of HCC1806 Sublines Co-expressing RFP and Rluc
Because we confirmed that HCC1806 cell line displays all molecular
features of B-TNBC, we selected this line for establishing an in vivo
model. The main goal of this part of the study was to assess the poten-
tial of HCC1806 cells to linearly expand at the orthotopic site (i.e.,
MFP in mouse), spontaneously metastasize from the MFP, respond
initially to cytotoxic therapy [29,47], and recur at high rate [52].
Because the sensitivity of tumor cell detection is the key parameter
for establishment of a metastatic model, we aimed to employ stable
expression of two sensitive fluorescent and bioluminescent reporters
achieved using nonviral, DNA integrating vector system, SB transposon
[53]. To this end, a transgenic cell line was engineered to co-express
RFP and Rluc and referred to as HCC1806-RR. We preferred to
engineer the subline with Rluc as alternative to the frequently used Fire-
fly luciferase because the light production by Rluc is ATP-independent
[54], which eliminates a potential problem with inaccurate reflection of
tumor and metastatic burden because of necrosis and reduced tumor
metabolism [55]. HCC1806 cells (1 × 105 per well) were co-transfected
with the following plasmids: a SB transposon encoding for RFP and
Rluc both transcriptionally regulated by a synthetic bidirectional pro-
moter (pKT2/RBiL, 500 ng); SB transposase (500 ng), and a limited
amount of a second transposon that conferred resistance to puromycin
(pKT2/Puro, 10 ng) to permit clonal selection. Two days after trans-
fection, cells were plated into puromycin supplemented medium, and
selection continued for 2 weeks with medium changes every 3 to 4 days.
At this point, RFP-expressing and puromycin-resistant clones were
isolated and replated at limiting dilution to derive 10 to 12 subclones
that were determined to have typical HCC1806 cellular morphology
(Figure 2, A and B), uniform expression of RFP (Figure 2C), and very
high expression of Rluc activity as reflected by >3000 RLU/s per cell
(Figure 2D). Several monoclonal isolates with these characteristics were
then tested for cell proliferation in vitro. Only those sublines that
showed an identical pattern and doubling time to the parental line
(Figure 2E) were selected for further studies.
HCC1806-RR Cells Exhibit Varying Levels of Sensitivity
to Commonly Used Chemotherapeutic Drugs
After verifying the basal nature of HCC1806 and characterizing its
tagged cell derivatives, we sought to establish the profile of drug sen-
sitivity of this model in vitro. Clinical studies indicate that different
TNBC subgroups are initially sensitive to cytotoxic drugs; however,
the recurrence rate of B-TNBC is typically higher than that of other
groups [14,52]. Hence, it is of interest to compare the drug sensitiv-
ity of basaloid with other TNBC subtypes because this information
could be useful for tailoring therapeutic approaches specifically for this
cancer type.
To initiate these studies, we compared the drug sensitivity of a
mesenchymal and a basaloid subtype of TNBC represented by
MDA-MB-231 and HCC1806 (and -RR derivatives) cell lines, re-
spectively. To determine responsiveness to commonly used anti-
cancer drugs, 5 × 104 MDA-MB-231 or HCC1806-RR cells were
seeded into wells of 24-well plates and allowed to adhere overnight
before supplementing the medium with escalating doses of (A)
nanoparticle-bound paclitaxel (nab-paclitaxel), (B) paclitaxel, (C)
perifosine, (D) doxorubicin, (E) cisplatin, or (F) erlotinib (Figure 3).
In addition, we also tested the sensitivity to anti–VEGF-A antibody,
bevacizumab, as it is used in conjunction with some cytotoxic drugs.
Viable cells remaining after 48 hours were enumerated to construct
Figure 2. Generation and characterization of HCC1806-RR in vitro. HCC1806-RR line was generated using the SB transposon system by
a co-transfection of transposon plasmids encoding for dual expression of RFP and Rluc or a puromycin resistance gene in combination
with SB transposase. (A, B) Morphology of expanded monoclonal cell populations was compared to the parental cell line by bright-field
microscopy. (C) Monoclonal isolates with identical morphology were then assessed for homogenous RFP expression using fluorescent
microscopy. (D) Average RLU/s per cell was calculated to ensure a linear correlation with luciferase activity measured in triplicate and
expressed as the mean RLU/s per cell ± SD. (E) All selected clones were assessed for unaltered growth pattern as compared with the
parental cell line. Each time point was performed in triplicate, repeated twice, and presented as the mean cell number ± SD. Student’s
t test analysis showed no statistical difference between the proliferation rates of the HCC1806-RR clone and the parental line.
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dose-response curves (Figure 3, A–F ) that were used to determine the
IC50 for each agent (Table 1).
The parental HCC1806 and -RR lines showed no differences in
drug sensitivity, indicating that tagging this line with RFP and Rluc
did not alter natural responsiveness to chemotherapeutic agents. In
contrast, comparison of MDA-MB-231 and HCC1806 lines showed
drastic differences in this regard. Although both lines were sensitive
to paclitaxel and nab-paclitaxel, the IC50 for taxanes of MDA-MB-
231 cells exceeded that of HCC1806 by 12.8-fold (Table 1), suggesting
that B-TNBC might be more sensitive to taxanes than mesenchymal
breast cancer subtype. The trend for increased sensitivity to cytotoxic
drugs of B-TNBC line was evident for all tested drugs with the excep-
tion of doxorubicin (Figure 3D and Table 1). HCC1806 cells were also
fairly sensitive to perifosine (the mitogen-activated protein kinase inhib-
itor) with IC50 of 600 nM (Figure 3C and Table 1). In contrast, two
other cytotoxic drugs, anthracycline doxorubicin and the alkylating
agent cisplatin, were significantly less potent for both mesenchymal
and B-TNBC lines with IC50 ranging between 2500 and 5000 nM
(Figure 3,D and F , and Table 1). These IC50 were 1000- to 3000-fold
higher than IC50 for taxane-based drugs. Finally, erlotinib and
bevacizumab, the inhibitors of EGFR and VEGF-A, respectively, were
largely ineffective in all tested concentrations at inhibiting growth of
either TNBC lines in culture (Figure 3F and Table 1).
This analysis demonstrated that both subtypes of TNBC are most
sensitive to taxanes, relatively resistant to doxorubicin and cisplatin,
and completely insensitive to erlotinib and bevacizumab. This study
also showed that mesenchymal and basaloid prototypes of TNBC
significantly differ in sensitivity to chemodrugs as evidenced by 2- to
12-fold differences in IC50 to individual agents (Table 1). This finding
further underscores the importance of characterizing TNBC subgroups
to identify drug sensitivity and chemoresistance mechanisms that could
be specific for each group.
Figure 3. Sensitivity of HCC1806-RR to various chemotherapeutics. MDA-MB-231 and HCC1806-RR lines were assessed for sensitivity
to the following chemotherapeutic drugs: (A) nab-paclitaxel, (B) paclitaxel, (C) perifosine, (D) doxorubicin, (E) cisplatin, and (F) erlotinib.
Each point represents the average percent of control ± SD derived from two independent experiments performed in duplicates.
Table 1. In Vitro Sensitivity of TNBC Lines to Chemotherapeutic Drugs.
Drug Mode of Action IC50 (nM) Fold Change in IC50
MDA-MB-231 HCC1806* MDA-MB-231 vs HCC1806
Nab-paclitaxel Microtubule stabilizer 10 0.78 12.82
Paclitaxel Microtubule stabilizer 12 0.78 15.38
Perifosine MAPK inhibitor 3,500 600 5.83
Doxorubicin DNA cross linker 625 5,000 0.12
Cisplatin DNA intercalator 10,000 2,500 4.00
Erlotinib EGFR inhibitor 150,000 75,000 2.00
Bevacizumab Anti–VEGF-A antibody No effect No effect N/A†
MAPK indicates mitogen-activated protein kinase.
*HCC1806 and the line derivatives HCC1806-RR isolates showed identical sensitivity to all tested drugs.
†N/A denotes not applicable.
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Orthotopic HCC1806-RR Tumors Show Linear Kinetics and
Spontaneous Metastasis to LN and Lungs
After establishing the basic parameters of HCC1806-RR line
in vitro, we next determined the growth pattern and metastatic po-
tential of these cells in vivo. To this end, we first screened several
monoclonal HCC1806-RR isolates for the ability to grow at the
MFP at a similar rate to the parental line. This was done to ensure that
high expression levels of RFP and Rluc did not alter in vivo growth
properties. Only those clones that showed an identical growth pattern
to unmodified HCC1806 line were selected for the further studies.
One example of such clone is shown in Figure 4A.
Modification of HCC1806-RR cells with Rluc provided an opportu-
nity to use whole-body imaging to monitor tumor burden andmetastasis
in live animals or a luminometer to quantify metastasis in organ homog-
enates after sacrifice. The in vivo growth potential of HCC1806-RR was
monitored by injecting animals with coelenterazine (2 mg/kg) i.v. and ex-
posing them to a charged-coupled device (CCD) camera (Xenogen-100)
5 minutes later. Rluc activity was detected as light emitted from the
tumor cells and acquired as a pseudo-color image superimposed over
a black andwhite photograph of the animal. Allmice (n = 5) demonstrated
very high Rluc activity at the primary site with the majority of mice
simultaneously showing metastases to inguinal ILNs. Representative
images of mice bearing HCC1806-RR tumors are shown in Figure 4B.
We next determined metastatic distribution by measuring protein-
normalized Rluc activity in all major organs including LN, heart,
lung, liver, kidney, spleen, and brain. Consistent with clinical obser-
vations, the highest metastatic incidence was in ILNs and lungs that
were positive in 80% and 90% of the mice (n = 10), respectively
(Figure 4C). Liver and kidney were minor metastatic sites detected in
20% and 10% of the mice. Other organs were negative at the time of
analysis when the average tumor volume was approximately 1100 mm3.
Analysis of metastatic burden per organ showed the highest burden in
ILN (2.34 × 105 ± 0.60 × 105 RLU/mg), followed by pulmonary
metastases with the mean value of 0.43 × 105 ± 0.08 × 105 RLU/mg
of total lung tissue protein (Figure 4D).
These studies demonstrate that the HCC1806-RR model mimics
the major clinical manifestations of metastatic breast cancer in human
patients including the ability to linearly expand at the mammary site
and spontaneously spread to ipsilateral regional LNs and to lungs from
the orthotopic site.
Figure 4. Characterization of HCC1806-RR tumor growth and metastasis in vivo. (A) Parental HCC1806 and HCC1806-RR tumors were
implanted into the MFP of female nu/nu mice. Tumors were measured two to three times per week, and each point represents the
average tumor volume ± SEM. Analysis of tumor growth of parental and modified lines by Student’s t test showed no statistically
significant differences. (B) Tumors bearing orthotopic HCC1806-RR were injected i.v. with 2 mg/kg Rluc substrate (coelenterazine) that
was allowed to circulate for 5 minutes. Then, mice were immobilized and imaged for 3 to 5 minutes. The black and pink arrows indicate
the primary tumor and the positive inguinal LN, respectively. (C) All major organs were tested for the presence of metastasis by mea-
suring Rluc activity. Each bar represents the percentage of metastatic incidence to respective organ in the group of 10 mice. (D) The
metastatic burden was measured by Rluc activity normalized per mg of total protein, as described under Materials and Methods. Each
black dot represents an animal testing positive for tumor burden from the indicated organs. The black bar indicates the mean burden in
each organ for the entire group (n = 10).
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HCC1806 Tumors and Their Derivatives Induce Highly
Abnormal Vasculature
As recapitulated by the HCC1806-RR model (Figure 4), breast
cancers have the propensity to metastasize to the proximate LNs
followed by metastasis to distant organs. The lymphatic metastasis
is influenced by tumor-induced lymphangiogenesis [56], whereas sys-
temic metastasis is determined, in part, by specific properties of tumor
blood vessels [57]. To the best of our knowledge, no previous study
has examined the structural properties of B-TNBC although such
analysis can provide insights into mechanisms of the high metastatic
potential and frequent recurrence associated with this cancer group
[29,47]. The novel HCC1806-RR B-TNBC model established here
provided us with an opportunity to characterize the type, location,
and structural properties of blood and lymphatic vessels induced by
this tumor in vivo.
Because the lymphatic metastasis is dominant in this model, we first
characterize lymphatic vessels using an antibody against a lymphatic
marker, LYVE-1. Some tumor sections were co-stained with antibody
against Rluc to determine the sustainability of this marker expression
in vivo and for demarcation of tumor-host borders. Figure 5A shows
that Rluc was homogeneously expressed in all tumor cells (green),
which permitted clear identification of tumor margins. Co-staining
with anti–LYVE-1 antibody revealed the absence of intratumoral
lymphatic vessels in all HCC1806 or HCC1806-RR tumors examined
(n = 10), although high density of LYVE-1+ structures was found in
the host tissue adjacent to the tumor border (Figure 5A). Additionally,
the peritumoral space was populated by numerous single cells and
clusters positive for LYVE-1 (Figure 5B). These observations sug-
gest that breast tumors modeled by HCC1806 metastasize to LNs
exclusively through peritumoral lymphatic vessels whose generation
might be aided by LYVE-1–positive progenitors mobilized to the
tumor-host interface.
We next examined the blood vessels induced by HCC1806 tumors
using a pan-endothelial marker of blood vascular endothelium,
MECA-32. This staining revealed three striking abnormalities of
the HCC1806-induced blood vasculature. First, in all examined
tumors (n = 10), the tumor center was nearly devoid of MECA-32+
vascular structures being replaced by clusters of MECA-32+ isolated
cells sporadically appearing throughout the central region (Figure 5C ,
white arrows). Second, the extensive blood vascular network present at
the tumor periphery was chaotically arranged in the loosely connected
plexuses (Figure 5D) that neither resembled the organized network in
the normal MFP nor vascular pattern in other tumors (e.g., MDA-
MB-231). These plexuses were surrounded by avascular space and
might only be partly functional, as indicated by a necrotic spot appear-
ing at its center (Figure 5D, asterisk). Third, many blood vessels were
extremely dilated and have various morphologic deformities including
multiple lumens (Figure 5E , white arrowheads). The severe structural
disturbances in the HCC1806 tumor–induced blood vasculature were
particularly conspicuous when compared side by side with normally
sized and shaped capillaries that occasionally were present in the same
field (Figure 5E , compare structures indicated by arrows and arrow-
heads). Although dilation of blood vessels is a known feature of tumor
vasculature [58], HCC1806 tumors induce extraordinarily dilated
vessels. This is demonstrated by the fact that the total area of vascular
network of HCC1806 tumors was 8-fold larger than that of MDA-
MB-231 tumors (4.16 ± 0.62 μm2 vs 0.51 ± 0.07 μm2) and 21-fold
larger than of the normal MFP (Figure 5F). Collectively, these observa-
tions point out to clear pathophysiological differences between
HCC1806 and MDA-MB-231 tumor vasculature and underscore the
unique vascular properties of B-TNBC that might be critical for pro-
moting metastatic spread, impeding drug delivery, and supporting
tumor recurrence after initial responsiveness to the drugs.
HCC1806-RR Cells Express Low Levels of VEGF-A and
VEGF-A Receptors that Are Upregulated by Nab-Paclitaxel
The structural abnormalities of HCC1806-induced blood vessels
suggested that this tumor line might be deficient in the production of
essential angiogenic factors such as VEGF-A [59]. To test this hypothesis,
we determined secretion of VEGF-A protein in HCC1806 cells cultured
for 24 hours in growth medium. We found that both HCC1806 and
HCC1806-RR produce an average of 26 ± 3 pg of VEGF-A nor-
malized per 106 cells (Figure 6A, time 0). This value is 12-fold lower
than that determined for MDA-MB-231 cells under identical condi-
tions [36], suggesting that a relatively low level of VEGF-A might be
partly responsible for vascular deficiencies observed in HCC1806
tumors in vivo (Figure 5, C–E).
We previously showed that some breast carcinoma lines not only
express VEGF-A receptors but also upregulate both VEGF-A and
VEGFR-2 or neuropilins in response to paclitaxel therapy [36,37].
We, therefore, determined whether HCC1806 followed the similar
response to cytotoxic drugs. To this end, we treated cells with 10 nM
nab-paclitaxel and collected medium and mRNA at 2, 6, 24, 48, and
72 hours after drug addition, for VEGF-A ELISA and RT-qPCR
assays, respectively. Both assays showed that VEGF-A and VEGFR-2
as well as neuropilin-2 (NP-2) were drastically increased after addition
of the drug, in particular, at the 24-hour time point (Figure 6). At this
time, we observed 10- to 30-fold increase in mRNA for VEGF-A and
both receptors and nearly a two-fold increase in secreted VEGF-A pro-
tein (Figure 6B). This finding suggests that, analogous to our findings
in other breast carcinoma lines [36,37], taxane therapy, while effec-
tive in killing the tumor cells, also induces coincident expression of
VEGF-A and its receptors, thus potentially creating an autocrine pro-
survival loop. This observation suggests that eliminating a blunting
effect of VEGF-A with a neutralizing antibody may significantly im-
prove the response of B-TNBC tumors to taxanes in vivo, as reported
in other breast cancer models [37]. To further explore this hypothesis,
we tested whether the effect of nab-paclitaxel is modulated by the ad-
dition of VEGF-A and negated by the addition of bevacizumab. We
found that, indeed, addition of 10 ng/ml VEGF-A165 shifts the IC50
by approximately 300%, whereas bevacizumab (2 μg/ml) shifts the
curve back to control demonstrating its capability to neutralize exoge-
nous VEGF-A (Figure 6C ).
We then asked the question whether this pro-survival effect is
dose dependent and is equally endowed by the two major isoforms
of VEGF-A, V165 and V121. The results showed that the pro-survival
effect is dose dependent with maximal effect achieved at concentra-
tions above 1 ng/ml and that V165 is significantly more efficacious than
V121. At concentrations above 25 ng/ml, exogenous V165 afforded
survival of 2.5-fold more cells as compared with nab-paclitaxel alone
(Figure 6D). Cultured HCC1806 cells, however, produce signifi-
cantly less VEGF-A (Figure 6, A and B), raising the question whether
the pro-survival effect promoted by 10 to 100 ng/ml VEGF-A is
relevant to in vivo conditions. To answer this question, we compared
the amounts of mRNA and protein produced by HCC1806 cells
in culture and by HCC1806 tumors in vivo. The results showed
a significant difference in production of VEGF-A at both mRNA
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Figure 5. Characterization of lymphatic and blood vessels in HCC1806-RR model. (A) The staining for Rluc expression (green) homo-
geneously identified all HCC1806-RR tumor cells and clearly demarcated a tumor-host interface border denoted by the white dotted line.
Co-staining for LYVE-1 showed that all lymphatic vessels (red) are located in the peritumoral space and do not penetrate the tumor
mass. This image was acquired at 200×. (B) In addition to lymphatic vascular structures, the peritumoral space was heavily populated
by LYVE-1+ single cells (red) that were mobilized to tumor margins but did not penetrate the tumor. This image was acquired at 100×.
(C) The center of the tumor was devoid of blood vascular structures, but individual cells stained positively for MECA-32 (red and denoted
by white arrows). This image was acquired at 400×. (D) MECA-32 vascular structures were mainly located at the periphery of the tumor
and were composed of large disorganized plexuses. These vessels may have reduced functionality, as suggested by necrosis frequently
observed at the center of most plexuses (indicated by lack of blue 4,6′-diamidino-2-phenylindole staining and denoted by a white asterisk).
This low-magnification image was acquired at 40×. (E) Additionally, MECA-32–positive blood vessels (red) were hyperdilated and exhib-
ited various structural malformations including multiple lumens (white arrowheads). Note the substantial differences in size and shape
between the hyperdilated and malformed vessel (white arrowheads) and few “normal type” blood capillaries (white arrows) that co-exist
in the same tumor region. This image was taken at magnification of 200×. (F) The total area of blood vessels wasmeasured using Image J
software based on four images acquired from four different tissue samples of normal MFP, MDA-MB-231 tumors, and HCC1806-RR
tumors. The asterisk indicates a statistically significant difference measured by Student’s t test (P< .01) between the mean total vascular
area in HCC1806-RR tumors and that in MDA-MB-231 tumors or normal MFP.
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and protein levels in culture as opposed to in situ settings (Figure 6,
E and F ). When normalized per expression of mRNA of β-actin
(Figure 6E ) or mg of total protein (Figure 6F ), in vivo grown tumors
transcribed 11.2-fold more VEGF-A transcripts (the average of three
tumor samples) and increased correspondingly VEGF-A protein pro-
duction by 16.8-fold (n = 3). Given the nab-paclitaxel capacity to in-
crease VEGF-A expression nearly 30-fold (Figure 6B), these results
suggest that the local concentration of VEGF-A in the local environ-
ment of HCC1806-treated tumors can reach 20 to 50 ng/mg total pro-
tein. Therefore, it is plausible that VEGF-A induced by paclitaxel can
play a deciding role in negating drug-mediated death leading to the
hypothesis that anti–VEGF-A antibody can increase the efficacy of
cytotoxic therapy.
Combination Nab-Paclitaxel/Bevacizumab Therapy Is
Significantly More Efficacious in Suppression of HCC1806
Tumor Growth and Metastases Compared to Either
Agent Alone
Because we observed paclitaxel-mediated up-regulation of VEGF-A in
HCC1806 cells in vitro (Figure 6), we hypothesized that bevacizumab,
an anti–VEGF-A antibody, should improve suppression of HCC1806
tumors when combined with cytotoxic therapy in vivo. It should be
noted that expression of VEGF-A in cultured cells is limited by the ab-
sence of host cells and other elements of the tumor environment that
increase VEGF-A production nearly 20-fold compared to cells cultured
in vitro (Figure 6). This observation strengthens our hypothesis that is
further supported by previously reported success using this combined
Figure 6. The effect of nab-paclitaxel on VEGF-A expression in HCC1806-RR cells in vitro. (A) ELISA was used to measure VEGF-A protein
in conditioned medium of untreated HCC1806-RR cells (0 hours) and those treated for 2, 6, 24, 48, and 72 hours with nab-paclitaxel
(10 nM). Statistically significant increases in secreted VEGF-A protein were detected at 24, 48, and 72 hours after initiation of cytotoxic
treatment. VEGF-A secretion was measured in pg and normalized per 1 million cells. Each ELISA was performed in duplicate, and the
experiment was reproduced twice yielding the mean presented values ± SD. (B) Untreated and nab-paclitaxel–treated HCC1806-RR cells
were also quantitatively assessed for VEGF-A, VEGFR-2, and NP-2 transcript levels by RT-qPCR. Asterisks at 24 hours indicate a significant
up-regulation of mRNA for both VEGF-A and its receptors, VEGFR-2, and NP-2 at a 24-hour time point. RT-qPCR assays were performed in
duplicate wells and repeated three times. Results are presented as the mean values from three experiments ± SD. (C) HCC1806-RR cells
were treated with nab-paclitaxel (0.19–25 nM) alone or in combination with 10 ng/ml VEGF-A165, 5 μg/ml bevacizumab, or a combination
of all three. Statistically significant pro-survival shift by exogenous VEGF-A165 is indicated by asterisk (P < .001). Each point was per-
formed in duplicate wells in two independent experiments and is represented as the mean value ± SD. (D) The pro-survival benefit of
VEGF-A121 and VEGF-A165 was compared under constant nab-paclitaxel treatment (5 nM). The red bar indicates the IC50 of nab-paclitaxel
alone. Asterisk indicates a statistically significant increase in survival from nab-paclitaxel alone to nab-paclitaxel treated with either VEGF-
A121 or VEGF-A165. The symbol “#” indicates a statistically significant increase in enhanced survival between VEGF-A121 and VEGF-A165.
Each assay was performed in duplicate wells and in two independent experiments, and the results are represented as themean value ± SD.
(E) Human and mouse VEGF-A levels were measured by RT-qPCR from HCC1806-RR cells and from three HCC1806-RR tumors. The black
portion of the bar indicates the fold increase in human VEGF-A expression compared to the cells. The white portion indicates the increase in
mouse transcript levels compared to the human VEGF-A expression from cultured cells. Each assay was performed in duplicate wells and
repeated three times. (F) Protein expression for VEGF-A was compared from HCC1806-RR cells and from three HCC1806-RR tumors. Each
bar represents the mean ng/mg protein of VEGF-A. Each ELISA was performed in duplicate and was repeated twice. Each bar is the mean
VEGF-A expression ± SD.
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treatment in both MDA-MB-231 andMDA-MB-435 models [36,37].
Moreover, synergistic effect of bevacizumab and paclitaxel therapy has
been widely reported in a variety of other cancer models [37,60,61] and
clinical trials [62,63]. However, combination of nab-paclitaxel and
bevacizumab has not been previously assessed in a B-TNBC experi-
mental model, and currently, it is not a routine therapeutic approach
to patients with TNBC in clinics.
To determine the efficacy of the nab-paclitaxel/bevacizumab treat-
ment in the HCC1806 model, we allowed HCC1806-RR tumors to
reach ∼150 mm3 in volume before randomizing mice to four groups
(seven to eight mice each) and treating them with saline (control),
nab-paclitaxel alone (10 mg/kg, i.v., daily for five consecutive days),
bevacizumab alone (4 mg/kg, i.p., biweekly), or nab-paclitaxel in
combination with bevacizumab. Drug response was monitored by
monitoring tumor volume measured every 3 days (Figure 7A and
Table 2). Tumors formed in saline-treated mice reached maximal
volume in 38 days with a growth rate of 56.2 ± 4.4 mm3 per day.
Mimicking the IC50 study in vitro, bevacizumab alone had no effect
on tumor growth, whereas nab-paclitaxel alone reduced the growth
rate by nearly five-fold (Figure 7A and Table 2). Nab-paclitaxel re-
duced tumor volume up to 90% as compared with saline-treated
controls (P < .001, Table 2). However, 100% of tumors (n = 8)
recurred upon cessation of therapy (Figure 7A, second red arrow), a
pattern reminiscent of clinical behavior of TNBC [14,29,52]. Sig-
nificantly, nab-paclitaxel combined with bevacizumab resulted in a
substantially better outcome as evidenced by 50% of complete re-
sponses (CRs) in a combination group (Table 2) as compared with
0% CR (i.e., 100% recurrence) in all other groups.
Figure 7. The effect of nab-paclitaxel and bevacizumab combination therapy on tumor growth and metastasis in HCC1806-RR model
in vivo. (A) HCC1806-RR tumors were implanted into the MFP and monitored two to three times per week. Each line represents the
mean daily tumor volume ± SE. The black and red arrows indicate the beginning of treatment and recurrence after nab-paclitaxel treat-
ment, respectively. (B) ILN, (C) CLN, and (D) lungs were assessed for metastatic burden. Each dot represents the metastatic burden for
individual mice in each group as measured by luciferase activity normalized per mg of total protein. The results are expressed as mean
RLU/mg protein. The black bar indicates the mean metastatic burden for each group (n = 10). Statistically significant differences in
metastatic burden were identified by a Wilcoxon ranked sums test (*P < .05, **P < 0).
Table 2. Effect of Combination Therapy on Growth of HCC1806-RR Tumors In Vivo.
Treatment N Drug Dose (mg/kg) Mean Tumor Volume (mm3) % Inhibition of Control TGD* vs Control % CR† P value vs
Control ABX
Control 7 – 1799 ± 169 – – 0 – –
Bev‡ 8 4 2126 ± 297 0 0 0 NS‡ –
ABX‡ 8 10 180 ± 55 90 >28 0 <.001 –
ABX + Bev 8 10/4 0 100 >28 50 <.001 .024
*Tumor growth delay (TGD) is defined as number of days that delayed the mean tumor volume per group reaching 1000 mm3 as compared with the saline-treated control groups.
†CR was defined as the absence of palpable tumor at the original tumor injection site at the end of the experiment.
‡Bev, ABX, and ABX + Bev denote treatment with bevacizumab, nab-paclitaxel, and combination of the two drugs, respectively. NS stands for not significant.
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We next compared the efficacy of combined drugs and mono-
therapies on metastatic incidence and burden at two major metastatic
sites identified in the earlier studies (Figure 4). ILN and pulmonary
metastases were detected in 100% of saline-treated mice, whereas
CLN metastases were detected in 71% of the control group. ILN
in the control mice had the highest metastatic burden (79 × 106 ±
143 × 106 RLU/mg protein), followed by burden in CLN and lungs
with 1.6 × 106 ± 1.9 × 106 and 0.05 × 106 ± 0.02 × 106 RLU/mg pro-
tein, respectively. This burden was largely unaffected by bevacizumab
alone, whereas nab-paclitaxel alone significantly reduced the amount
of metastases in LNs but not in lungs (Figure 7). Once again, com-
bination therapy was more efficacious than a cytotoxic or an anti-
angiogenic drug alone as demonstrated by a 20.7-fold and a 2.7-fold
reduction in burden in the ILN and lungs, respectively. In comparison,
nab-paclitaxel alone reduced burden in ILN by 7.1-fold but had no
effect on the burden on pulmonary site. Bevacizumab alone reduced
ILN burden by less than 2-fold and had no impact on metastatic
growth in other sites.
Importantly, combination therapy was efficacious not only in re-
ducing the burden of metastases but also their incidence. The inci-
dence in ILN, CLN, and lungs was reduced to 50%, 0%, and 13%
with P values ranging from .007 to .001 (Table 3), indicating a sta-
tistically significant benefit of nab-paclitaxel/bevacizumab therapy in
eradicating both regional and distant metastatic lesions. In compar-
ison, bevacizumab alone had no effect on incidence in any of the
three metastatic sites, and nab-paclitaxel alone was only effective in
suppressing metastasis to CLNs but not to other sites (Table 3).
In summary, we showed here for the first time that a moderate
dose of nab-paclitaxel (10 mg/kg) in combination with bevacizumab
(4 mg/kg) was efficacious against B-TNBC as demonstrated by com-
plete sustainable regressions of primary tumors in half of the treated
animals and 50% to 100% reduction in incidence of mice with
metastatic organs. These data suggest that a similar strategy can be
beneficial for treating human patients with B-TNBC.
Discussion
B-TNBC is one of the most aggressive subtypes of breast tumors
associated with high incidence of recurrence and metastasis and, con-
sequently, with reduced rates of patient survival [10,11,13,14]. The
main challenges to successful B-TNBC treatment are the lack of sur-
face targets (i.e., ER and HER2) for available molecular therapies and
subtype-specific genetic alterations that promote rapid recurrence
after a seemingly successful therapy [6,13,14,28]. Despite the undis-
putable need for better understanding of the unique B-TNBC biol-
ogy and identification of new targets for treatment, most currently
available animal models do not adequately mimic this phenotype.
We, therefore, sought to establish a new B-TNBC model that faith-
fully recapitulates both the genetic signature of B-TNBC and its main
clinical manifestations.
To this end, we first identified a bona fide human TNBC cell line
that expresses basal markers and exhibits biologic behavior in vivo con-
sistent with the phenotype of clinical B-TNBC. Next, we engineered a
subline with stable expression of RFP and Rluc (i.e., HCC1806-RR) to
enable sensitive in vivo detection and quantification of tumor growth
and metastases. We validated that the HCC1806-RR line had iden-
tical morphology, growth, and metastasis patterns to those of the pa-
rental line. Next, we compared the drug sensitivity of this line with
MDA-MB-231, a line that is currently thought to represent TNBC
[33,34,38,39]. This was followed by a detailed characterization of the
growth, metastasis, and vascular patterns in orthotopic HCC1806-RR
tumors in vivo. Lastly, using the validated B-TNBC model, we dis-
covered that this type of tumor may recover from cytotoxic therapy
through induction of autocrine pro-survival VEGF-A·VEGFR loop, a
finding that provides evidence-based rationale for combining cytotoxic
and anti–VEGF-A therapies. Collectively, this study presents a new
metastasis-quantifiable B-TNBC model that displays essential features
of the corresponding human disease and is suitable for in-depth molec-
ular analyses as well as for testing new treatments.
Currently, the MDA-MB-231 cell line is the most frequently de-
scribed TNBCmodel in more than 50 publications (e.g., as presented
in [39,40,64,65]). This is based on evidence showing that this line
lacks ER, PR, and HER2 [32,66] while being positive for a TNBC
marker, EGFR [20,66]. Both of these properties have been confirmed
in the present study (Figure 1). However, on the basis of indepen-
dent hierarchical clustering analyses [20], MDA-MB-231 cells express
vimentin and a variety of other mesenchymal-specific markers [20],
classifying this line as mesenchymal [20] or mesenchymal stem–like
[31] subgroup. This classification is supported by our findings dem-
onstrating lack of expression of bona fide basal markers such as cyto-
keratins 5, 6, 14, and 17 (Figure 1), a cluster of basal epithelial proteins
typically detected in clinical specimens of B-TNBC [3,6,18,19]. More-
over, several studies suggested that the genetic profile of MDA-MB-231
line is consistent with a rare group of breast tumors occurring in less
than 0.2% of patients [44] that is classified as metaplastic, sarcomatoid,
or spindle carcinoma of the breast [20,41,42]. On the basis of this
information and independent marker analysis shown here (Figure 1),
we concluded that MDA-MB-231, albeit being a convenient line
for studies of tumor lymphangiogenesis and lymphatic metastasis
[36,37], may not be an ideal model for analyzing biologic behavior
of clinical B-TNBC.
Hence, the primary goal of this work was to establish a new model
that reproduces both the molecular signature and the principal clin-
ical manifestations of B-TNBC. HCC1806 was identified in our
preliminary studies as a line that complied with the criteria for estab-
lishing such a model (Table 4). Not only does the HCC1806 line
lack ER, PR, and HER2, an essential, but insufficient requirement
for modeling B-TNBC, it also does not express mesenchymal markers
Table 3. The Effect of Combination Therapy on Metastatic Incidence of HCC1806-RR Tumors.
Treatment Drug Dose (mg/kg) Incidence N /Total (%) P Value vs
Control ABX
ILNs
Control – 7/7 (100) – –
Bev* 4 8/8 (100) NS* –
ABX* 10 6/8 (75) NS –
ABX + Bev 10/4 4/8 (50) .077 NS
CLN
Control – 5/7 (71) – –
Bev 4 3/8 (38) NS –
ABX 10 1/7 (13) .041 –
ABX + Bev 10/4 0/8 (0) .007 NS
Lung
Control – 7/7 (100) – –
Bev 4 8/8 (100) NS –
ABX 10 8/8 (100) NS –
ABX + Bev 10/4 1/8 (13) .001 .001
*Bev, ABX, and ABX + Bev denote treatment with bevacizumab, nab-paclitaxel, and combination
of the two drugs, respectively. NS stands for not significant.
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(e.g., vimentin) while being positive for all four basal cytokeratins 5, 6,
14, and 17 (Figure 1). In contrast, MDA-MB-231 line is positive for
vimentin and lacks all basal cytokeratins (Figure 1 and Table 4). More-
over, biologically, these two lines display drastic differences in sensitiv-
ity to chemotherapeutic drugs (Figure 3 and Table 1) with HCC1806
cells being 2- to 12-fold more sensitive compared with MDA-MB-
231. This is consistent with paradoxical behavior of clinical B-TNBC
that is reported to be fairly sensitive to cytotoxic treatments despite the
subsequent heightened recurrence rate [6,13,14,28]. Both of these
parameters were reproduced in the in vivo HCC1806 model that,
albeit being more sensitive to taxanes than MDA-MB-231 by three-
to four-fold [36,37], quickly recurs after chemotherapy within 4 to
5 days (Figure 7A). The fact that these biologic characteristics are
consistent with the behavior of clinical B-TNBC [29,47] supports
the validity of the selected line and indicates the potential to use this
model for dissecting mechanisms of recurrence.
Another nonclinical advantage of the HCC1806-RR model is its
dual labeling with Rluc and RFP (Figures 2, 4, and 5), which pro-
vides a unique tool set for assessing growth, metastasis, identification,
and quantification of human tumor cells in vivo by immunohisto-
chemistry, fluorescence, and bioluminescence methodologies. We
validated in both culture and in vivo settings that HCC1806-RR
had unaltered morphology and growth identical to the parental cells
(Figures 2E and 4A). We regard this as an important, and often over-
looked, requirement for a reliable experimental cancer model because,
in our hands, cell line modifications with stable expression of non-
mammalian proteins such as GFP, RFP, or luciferases may interfere
with basic properties of these lines. We, therefore, took precautions to
ensure that the selected derivatives do not deviate in any observable
properties from the parental cells. Some advantages of HCC1806-RR
model are illustrated in Figures 2, 4, and 5: Double labeling provides
two independent measures for monitoring tumor growth, Rluc-
mediated ATP-independent [54] noninvasive monitoring of metas-
tases (Figure 4B), their quantifiable burden, incidence and organ
distribution, and a clear demarcation of tumor border juxtaposed to
peritumoral tissue of the host.
We took an advantage of this model to initiate studies on HCC1806
tumor vasculature whose unique features may contribute to chemo-
resistance, recurrence, and metastasis associated with B-TNBC. To
our knowledge, no other study had examined the specific properties
of TNBC-induced vessels and compared them with those in other
tumors or normal tissues. We discovered that although the HCC1806
model features prominent lymphatic metastasis (Figure 4 and Table 3),
none of the examined tumors had intratumoral LYVE-1+ lymphatic
vessels (Figure 5, A and B). This is consistent with growing evidence
from preclinical [67,68] and clinical studies [69,70], indicating the
sufficiency of peritumoral lymphatic vessels to deliver tumor cells to
regional LNs [71]. Most tumors displayed not only LYVE-1+ vascular
structures but also accumulation of LYVE-1+ single cells at the tumor-
host interface (Figure 5B). Although the identity of these cells would
require an additional study, their peritumoral location and interaction
with lymphatic vessels suggest tumor-induced recruitment of lymphatic
endothelial cell progenitors reminiscent of macrophage-derived pro-
genitors mobilized to sites of cancer [72] and inflammation [73]. If
this observation is generalized to clinical B-TNBC, it might provide
an opportunity to repress lymphatic metastasis by interfering with
generation of peritumoral lymphatics.
We also examined the blood vasculature in HCC1806 and
HCC1806-RR tumors. Both types of tumors induce an identical and
highly abnormal blood vascular network characterized by dissociated
MECA-32+ endothelial cells (Figure 5C), highly heterogeneous distri-
bution of blood vessels within the tumor mass, highly irregular vascular
plexuses located intermittently with long stretches of avascular
areas (Figure 5D), structural deformities illustrated by multilumen
channels (Figure 5E , arrowheads), and extraordinarily dilated vessels
with area exceeding that of the normal MFP vasculature by 21-fold
(Figure 5F ). These abnormalities supersede even those induced by
MDA-MB-231 tumor vessels that, in turn, considerably differ from
vessels in normal mammary tissue. Because this is the first time that
B-TNBC vasculature has been analyzed in either clinical specimens
or an experimental model, we do not know whether HCC1806 vas-
cular abnormalities are typical for clinical B-TNBC or an idiosyncrasy
of HCC1806 tumor model. However, if vascular dilation and other
structural vascular irregularities are confirmed in clinical B-TNBC, this
might explain the propensity to metastasize [14], which can be en-
hanced by disruption of the endothelial barrier. Irregular vessel distri-
bution and vascular abnormalities can also explain, in part, the initial
sensitivity to chemodrugs because of vulnerability of poorly perfused
tumor tissue that develops necrosis even without treatment with cyto-
toxic drugs (Figure 5D, asterisk). Clearly, the comparison of the de-
scribed vascular features to those in clinical B-TNBC might open a
new platform for understanding unique patterns of chemoresistance,
recurrence, and metastasis in this type of tumors.
Lastly, we used this new model for assessing potential benefits of
nab-paclitaxel/bevacizumab combination therapy. We have previously
shown in two aggressive models of breast cancer (MDA-MB-231 and
MDA-MB-435) that addition of anti–VEGF-A antibody to nab-
paclitaxel significantly increases the curative potential of cytotoxic
therapy [37]. This combined therapy (but not each component alone)
eradicated large MDA-MB-231 tumors (>500 mm3) along with pre-
existing LN and lung metastases in more than 70% of the mice [37].
We showed that the likely mechanism for synergistic action may in-
volve taxane-induced stress response that hyperactivates the NF-κB
pathway leading to upregulated VEGF-A and its receptors [37]. We
hypothesized that a similar mechanism may exist in HCC1806 tumor
Table 4. Representation of Salient Features of Clinical B-TNBC by Cell Culture Models.
Hallmarks of Clinical B-TNBC MDA-MB-231 HCC1806-RR
Marker Expression
Negative for ER, PR, HER2/Neu
Positive for EGFR
Negative for vimentin
Positive for basal cytokeratins 5, 6, 14, and 17
Clinical Parameters
Lymphatic metastasis
Hematogenous metastasis
Initial sensitivity to chemotherapy
Recurrence after treatment
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cells. Examination of VEGF-A and its receptor transcripts showed
that while nab-paclitaxel kills some tumor cells (Figure 3) it coinci-
dently upregulates VEGF-A, VEGFR-2, and NP-2 in surviving cells
by 10- to 30-fold (Figure 6B). Accordingly, VEGF-A protein in the
conditioned medium of nab-paclitaxel–treated tumor cells was nearly
doubled as compared with controls (Figure 6A). These data are in line
with our previous findings in MDA-MB-231 and MDA-MB-435
models [37], suggesting a common mechanism for DNA damage stress
response responsible for generating a VEGF-A–mediated autocrine
loop that blunts response to cytotoxic therapy. The autocrine mech-
anism is, however, difficult to analyze in culture because in the absence
of host cells and three-dimensional environment, HCC1806 cells ma-
nipulated in vitro secrete 15- to 20-fold less VEGF-A than correspond-
ing tumors grown in vivo (Figure 6, D–F). In addition, the host cells
add roughly a third to the half of VEGF-A measured in tumors
(Figure 6E), further complicating the distinction between the autocrine
and paracrine mechanisms of VEGF-A–dependent promotion of
tumor growth. This is because VEGF-A receptors expressed on human
malignant cells equally bind both human and mouse-produced protein.
Given these experimental challenges, we can only suggest that both
autocrine and paracrine modes of VEGF-A action are likely to contrib-
ute to resistance to paclitaxel therapy although the exact contribution of
each of these mechanisms cannot be deduced from these studies.
Nevertheless, we demonstrate here in the new HCC1806-RR
model that the combination therapy reduced the recurrence rate by
half as compared with all other groups (Figure 7 and Table 2). Im-
portantly, the incidence of positive LNs and lungs was also reduced
in the combined therapy group, respectively, by 50% and 87%
(Table 3). These findings obtained in the validated B-TNBC model
strongly advocate for including bevacizumab, or similar VEGF-A
neutralizing agent, as a routine adjuvant for taxane-based therapy.
Conclusions
In summary, we present evidence for generation of a novel model for
human B-TNBC that grows at the MFP and spontaneously metas-
tasizes from the orthotopic site in mice. We provide a detailed char-
acterization of this model in both in vitro and in vivo settings. Our
data show many advantages of this model including close represen-
tation of molecular signature of clinical B-TNBC, its propensity to
recur, and high metastatic potential to LNs and lungs. These prop-
erties that create significant challenges in clinics might be addressed
in the future by analyzing the biologic mechanisms underlying the
aggressive phenotype of TNBC. Additionally, a double-labeled
HCC1806 system is fully validated for quantitative analysis of tumor
growth and metastasis in vivo, which should facilitate assessment of
new therapies. We, therefore, believe that the HCC1806-RR model
will be broadly used for unraveling unique B-TNBC biology and
designing effective strategies for eradication of this disease.
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Table W1. Sequences of Primers for RT-PCR.
Gene Symbol Primer Sequence Product Size (bp)
KRT 8 195
Sense 5′-CCGACGAGATCAACTTCCTC-3′
Antisense 5′-GGTACATGCTCTCAGCCTCA-3′
KRT18 386
Sense 5′-AGATTGACAATGCCCGTCTT-3′
Antisense 5′-CACTGTGGTGCTCTCCTCAA-3′
KRT 19 211
Sense 5′-TTTGAGACGGAACAGGCTCT-3′
Antisense 5′-AATCCACCTCCACACTGACC-3′
KRT 5 177
Sense 5′-TCTCGCCAGTCAAGTGTGTC-3′
Antisense 5′-ATAGCCACCCACTCCACAAG-3′
KRT 6 229
Sense 5′-CACCAAGACTGTGAGGCAGA-3′
Antisense 5′-GTAGGCAGCATCCACATCCT-3′
KRT 14 157
Sense 5′-GACCATTGAGGACCTGAGGA-3′
Antisense 5′-ATTGATGTCGGCTTCCACAC-3′
KRT 17 361
Sense 5′-CACCATGACCACCTCCATC-3′
Antisense 5′-CCAGTCACGGATCTTCACCT-3′
EGFR 198
Sense 5′-GGAGCCTCTTACACCCAGTG-3′
Antisense 5′-GCTTTCGGAGATGTTGCTTC-3′
VIM 323
Sense 5′-TGCAGGACTCGGTGGACTTC-3′
Antisense 5′-GAAGCATCTCCTCCTGCAAT-3′
VEGF-A 228
Sense 5′-CACATAGGAGAGATGAGCTTC-3′
Antisense 5′-CCGCCTCGGCTTGTCACAT-3′
VEGFR-1 101
Sense 5′-CTGTCATGCTAATGGTGTCCC-3′
Antisense 5′-TGCTGCTTCCTGGTCCTAAAATA-3′
VEGFR-2 208
Sense 5′-GACTTCAACTGGGAATACCC-3′
Antisense 5′-CATGGACCCTGACAAATGTG-3′
VEGFR-3 298
Sense 5′-AGCCATTCATCAACAAGCCT-3′
Antisense 5′-GGCAACAGCTGGATGTCATA-3′
NP-1 275
Sense 5′-CTGGTGAGCCCTGTGGTTTATTCC-3′
Antisense 5′-ACTAATGTCATCCACAGCAATCCC-3′
NP-2 198
Sense 5′-CAAACACTGTGGGAACATCG-3′
Antisense 5′-TTCTCAGGAAACCCAGGAGA-3′
β-Actin 276
Sense 5′-TGGGTCAGAAGGATTCCTATGT-3′
Antisense 5′-CAGCCTGGATAGCAACGTACA-3′
